Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor ...

Clarity, along with most Aussie biotech, has been caught in a double whirlwind: a sharp sell-off in US healthcare stocks and ...